MAIA Biotechnology, Inc. (MAIA) Stock Analysis & Investment Frameworks
MAIA Biotechnology, Inc. (MAIA) stock analysis on Invetso. Review MAIA Biotechnology, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
MAIA Biotechnology, Inc. Company Overview
- Exchange: New York Stock Exchange Arca
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
MAIA Biotechnology, Inc. Key Financial Metrics
- Market Cap: $67.92M
- Revenue: $N/A
- ROE: -211.15%
- ROIC: -131.68%
- Dividend Yield: N/A
About MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc. is a clinical-stage biotech firm dedicated to discovering, developing, and commercializing treatments for various cancers, with a primary focus on non-small cell lung cancer. The company's leading experimental compound, THIO, is an investigational drug candidate that utilizes a unique dual mechanism by targeting telomeres and stimulating an immune response. Established in 2018, the enterprise maintains its headquarters in Chicago, Illinois.
MAIA Biotechnology, Inc. Investment Frameworks
Invetso analyzes MAIA Biotechnology, Inc. (MAIA) across the following frameworks:
- MAIA Biotechnology, Inc. 10Y Growth Potential
- MAIA Biotechnology, Inc. Scenario Analysis
- MAIA Biotechnology, Inc. Risks & Opportunities
- MAIA Biotechnology, Inc. Economic Moat
- MAIA Biotechnology, Inc. Business Model
- MAIA Biotechnology, Inc. Management
- MAIA Biotechnology, Inc. SWOT Analysis
- MAIA Biotechnology, Inc. Porter's 5 Forces
- MAIA Biotechnology, Inc. PESTLE Analysis
- MAIA Biotechnology, Inc. ESG Analysis